The lawsuit, which was filed in the U.S. District Court for the District of Delaware yesterday, seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney’s fees, Redwood City, Calif.-based Nevro said.
“Nevro was founded in 2006 to develop meaningful advances in the treatment of chronic pain to improve patients’ lives. Intellectual property is the basis for innovation in health sciences given the long development timelines, investment, and risk required to bring meaningful advances to market. We are committed to ensuring continued innovation in health sciences by protecting our intellectual property,” Nevro prez & CEO Rami Elghandour said in a press release.
Stimwave has not yet officially commented on the suit.
Last November, Nevro said it was seeking a reversal and remand for spinal cord stimulation patent infringement case against Boston Scientific (NYSE:BSX) that was ruled on last summer.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.